Rituxan

Links to news articles on Rituxan .

Genentech applies for new Rituxan use -- 30 Mar 2006
...said Thursday they submitted an application to the Food and Drug Administration to get their cancer drug Rituxan approved as part of a first-line treatment ... BusinessWeek

Playing Catch-up -- Mar 28, 2006
...cancer drugs Gleevec and Avastin, for example, are already being used to treat cancers other than the ones for which they were originally approved. Rituxan was ... American Enterprise Institute,

Genentech Says 2006 Profit Will Rise as Much as 50% (Update2) -- Mar 17, 2006
Genentech said it expects the Rituxan cancer drug, approved for a new use March 1, and a blindness treatment that's under US Food and Drug Administration ... Bloomberg

Rituxan Promising for Chronic Graft-versus-Host Disease -- Mar 24, 2006
24 - For refractory chronic graft-versus-host disease (GvHD), Rituxan (rituximab) may ... reported Corey Cutler, MD, MPH, of the Dana-Farber Cancer Institute here ... MedPage Today,

No Apologies for Genentech's Prices -- Mar 24, 2006
...cancer. We're trying to cure the leading cause of death in this country. The expense needs to be seen in that context. One of your other big drugs is Rituxan, ... MSNBC

Woman's last hope tied up in red tape -- Mar 16, 2006
A study of 143 patients assigned to two groups -- patients who received either Zevalin or Rituxan, a similar drug that fastens to the cancer cells and tags ... Globe and Mail,

US Drug Sales Increase 5.4% In 2005, Expected To Rise At That Rate ... -- Feb 27, 2006
Biotechnology drugs, such as Genentech's Rituxan cancer treatment and Amgen's Aranesp anemia treatment, experienced a 17.2% increase in sales, rising to $32.8 ... Medical News Today (press release),

Cancer drugs can top $100,000 a year -- Mar 19, 2006
A new generation of high-tech cancer drugs is extending patients' lives, but the costs ... RITUXAN (Non-Hodgkin's lymphoma): $13,000 to $25,000 per treatment cycle ... Chicago Sun-Times,

Genentech expects 15 treatments in four years -- Mar 18, 2006
The company also hopes to get Avastin approved for breast, lung and kidney cancer, among other things. Genentech's Rituxan, which the FDA approved in 1997 for ... San Jose Mercury News,

Cancer drug Rituxan receives federal approval to treat rheumatoid ... -- Mar 1, 2006
For all uses - cancer and non-cancer - he forecasts US sales of Rituxan to increase from $1.8 billion last year to $2 billion this year, then grow to $2.3 ... San Jose Mercury News,

Cancer drug Rituxan receives federal approval to treat rheumatoid ... -- Mar 1, 2006
WASHINGTON – The nation's best-selling cancer drug has won federal approval as a ... more than eight years after the agency initially approved Rituxan to treat ... San Diego Union Tribune,

Ailing woman is offered care -- Mar 17, 2006
A study of 143 patients assigned to two groups -- patients who received either Zevalin or Rituxan, a similar drug that fastens to cancer cells and tags them ... Globe and Mail,

New Use for Cancer Drug OK'd -- Mar 1, 2006
Limited data about Rituxan's non-cancer uses and restrictions on its rheumatoid arthritis indication are expected to limit its near-term market potential ... Los Angeles Times,

US gives a second life to a major cancer drug -- Mar 1, 2006
NEW YORK Genentech and Biogen Idec have won US federal approval to sell their cancer drug Rituxan as a treatment for rheumatoid arthritis. ... International Herald Tribune,

Cancer Drug OK‘d As Arthritis Treatment -- Mar 2, 2006
...available in RA and other autoimmune diseases such as lupus, Rituxan could achieve billion (dollars-per-year) potential in non-cancer indications," Kantor wrote ... Olberlin,

Cancer drug approved to treat arthritis -- Mar 2, 2006
Limited data about Rituxan’s non-cancer uses and restrictions on its rheumatoid arthritis indication are expected to limit its near-term market potential ... Tracy Press,

FDA approves cancer drug for arthritis -- Mar 1, 2006
Rituxan, an expensive treatment for cancer but easier on the body than chemotherapy, can now be marketed to the often debilitating arthritis, The Washington ... United Press International

Cancer drug OK for type of arthritis; other uses studied -- Mar 2, 2006
A drug industry analyst said Wednesday that Rituxan's use for diseases other than cancer could make it a key long-term growth product for the two biotechnology ... Akron Beacon Journal,

Genentech, Biogen cancer drug approved for new indication -- Mar 2, 2006
Genentech (DNA.NYS) and Biogen Idec (BIIB) Wednesday announced that the US Food & Drug Administration (FDA) had approved their cancer drug, Rituxan, for the ... New Ratings

Feds OK Cancer Drug For Rheumatoid Arthritis -- Mar 1, 2006
Rituxan is already the nation's best-selling cancer drug, having won approval to treat non-Hodgkin's lymphoma more than eight years ago. ... KETV.com,

Cancer Drug Approved for Rheumatoid Arthritis -- Mar 1, 2006
...of a widely used cancer drug to treat cases of rheumatoid arthritis that do not respond to other therapies, the drug's makers said. Rituxan (rituximab) targets ... Forbes

Cancer drug receives federal nod to treat rheumatoid arthritis -- Mar 1, 2006
WASHINGTON The nation's best-selling cancer drug has won approval from the Food and ... The two companies said Rituxan should be used by patients who haven't had ... Eyewitness News,

TRACON Pharmaceuticals Assembles Industry-Leading Management Team ... -- Mar 15, 2006
A former co- chair of the Southwest Oncology Group (Lung Cancer Committee), Dr ... the regulatory filings that supported the approval of Rituxan® (rituximab) and ... Yahoo! News (press release)

Pentostatin, Cyclophosphamide, Rituxan® Active in Chronic ... -- Mar 10, 2006
Researchers from Memorial Sloan Kettering Cancer Center and the Cleveland ... chemotherapy agents pentostatin and cyclophosphamide and the biologic agent Rituxan. ... Cancer Consultants (press release),

Spectrum Pharmaceuticals Reports 2005 Financial Results and ... -- Mar 15, 2006
...in Rituxan(R) failures, is running at approximately 30 centers in the US. * During 2006, we expect to initiate a Phase 2 study in head and neck cancer and ... PR Newswire (press release),

Genentech Boosts Earnings Forecast; Shares Rise -- Mar 18, 2006
Genentech said it was looking at its new lung cancer drug Tarceva in pancreatic and breast cancers. The non-Hodgkin's lymphoma drug Rituxan, which recently won ... Los Angeles Times,

Genentech raises EPS forecast, approvals target -- Mar 17, 2006
...it was looking at its new lung cancer drug Tarceva in pancreatic and breast cancers. It will also study non-Hodgkin's lymphoma drug Rituxan, which recently won ... MSN Money

Pending Rituxan Arthritis Approval Means Little To Earnings -- Feb 27, 2006
...and Drug Administration will make a decision on the blockbuster drug to treat rheumatoid arthritis, the first non-cancer indication for Rituxan, which booked ... Forbes

Drug Gets New-Use Approval -- Feb 28, 2006
The drug, Rituxan, is among a new group of cancer treatments that are more precise and less toxic than older chemotherapy compounds. ... Washington Post,

Cancer drug to remedy arthritis -- Mar 3, 2006
WASHINGTON - The nation's best-selling cancer drug, Rituxan, has won federal approval as a treatment for rheumatoid arthritis patients for whom other, older ... Albuquerque Tribune,

Rituxan OK'd for Rheumatoid Arthritis -- Mar 1, 2006
Like other RA treatments, including methotrexate, Rituxan was first used to treat cancer. It's been used since 1997 to treat non ... WebMD

Drug approval boosts Genentech -- Mar 2, 2006
Kantor forecasts Rituxan sales for cancer and arthritis will grow to a total $2 billion this year and $2.3 billion next year. Kantor ... San Mateo Daily Journal,

Genentech and Biogen Legal Troubles - When It Rains It Pours -- Mar 8, 2006
Roughly 12,760 patients in the US have the form of cancer Rituxan was approved to treat. ... For cancer, Rituxan costs about $20,000 for a six-treatment course. ... OpEdNews

Top Cancer Drug Gets OK For Rheumatoid Arthritis -- Mar 1, 2006
...(AP) The nation's best-selling cancer drug has ... and Drug Administration action comes more than eight years after the agency initially approved Rituxan to treat ... CBS 5,

FDA Approves New Rituxan Use -- Mar 1, 2006
...for treatment of slow-growing non-Hodgkin’s lymphoma, a form of cancer, after a relapse. Earlier this month, the FDA expanded the use of Rituxan for treating ... Red Herring,

Rituxan Has Strong Potential Post-Approval -- Mar 1, 2006
...data for Rituxan become available in rheumatoid arthritis and other autoimmune diseases like Lupus, the drug “could achieve billion potential in non-cancer ... Forbes

Genentech, Biogen get added Rituxan OK -- Mar 1, 2006
FDA approval to market Rituxan to treat diffuse large B-cell lymphoma, an aggressive type of non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma is a cancer of the ... BusinessWeek

Genentech's Pipeline Gap Seen Limiting Upside -- Mar 20, 2006
...analyst noted that Genentech plans to move forward with its experimental drug, second-generation anti-CD20, the successor drug to cancer blockbuster Rituxan. ... Forbes

Genentech/Biogen Idec: Rituxan further expands its options -- Mar 2, 2006
...than 730,000 patients have already been treated with rituximab worldwide, in its cancer indication. This gives physicians confidence in Rituxan's safely profile ... Pharmaceutical Business Review

FDA Approves First Rheumatoid Arthritis Ind ication for Rituxan ... -- Mar 1, 2006
MabThera/Rituxan is already available to physicians in the US and Europe for the treatment of a form of lymphatic cancer called non-Hodgkin's lymphoma (NHL). ... PharmaLive.com (press release),

Off-label usage of drugs gets scrutinized -- Mar 3, 2006
...to prescribe Rituxan for arthritis. Use: To treat some forms of non-Hodgkin's lymphoma. Approved Tuesday for rheumatoid arthritis. Cost: For cancer, about ... San Diego Union Tribune,

Rheumatoid Arthritis Drug Is Approved -- Feb 28, 2006
Genentech and Biogen Idec won federal approval yesterday to sell their cancer drug Rituxan as a treatment for rheumatoid arthritis. ... New York Times,

Genentech, Biogen Idec Gain Approval Of Rituxan In RA -- Mar 1, 2006
...approved Rituxan (rituximab) for rheumatoid arthritis, broadening the therapeutic antibody’s label and potentially its revenue. Long sold as a cancer therapy ... BioWorld Online (subscription),

FDA clears Rituxan for rheumatoid arthritis -- Mar 1, 2006
Genentech and Biogen Idec won approval to market their cancer drug Rituxan as a treatment for moderately-to-severely active rheumatoid arthritis yesterday, an ... Pharma Times (subscription),

Genentech: Good Medicine -- Mar 1, 2006
...to expand the use of its breast cancer drug, Herceptin. The company got two pieces of good news this week: The FDA said its lymphoma drug, Rituxan, could be ... Kiplinger.com,

Roche poised to exploit new arthritis opportunity -- Mar 1, 2006
Regulators gave the green light on Tuesday for Roche's top-selling cancer drug, Rituxan or MabThera, to be used as a treatment for the crippling inflammatory ... Reuters

MAb Causes Reactions In Phase 1; Six In Hospital -- Mar 15, 2006
...several were developed by South San Francisco-based Genentech Inc.: Rituxan, for non-Hodgkin’s lymphoma; Herceptin, for metastatic breast cancer; Xolair, for ... BioWorld Online (subscription),

Lymphoma drug FDA-approved for arthritis -- Mar 2, 2006
1, 2006 – The FDA announced today that it has approved the cancer drug Rituxan® for treatment of patients with moderate-to-severe rheumatoid arthritis (RA ... Cancerfacts.com,

Business News in Brief -- Mar 2, 2006
An industry analyst said Wednesday that Rituxan's use for diseases other than cancer could make it a key long-term growth product for the two biotechnology ... North County Times,

Roche Drug Approved for Rheumatoid Arthritis -- Mar 1, 2006
Roche, which generates around 40% of its pharmaceutical sales with cancer drugs, is ... Rituxan will be marketed to treat rheumatoid arthritis patients who aren't ... Smartmoney.com

RQ-PCR Positivity Predicts Relapse of Mantle Cell Lymphoma after ... -- Mar 9, 2006
...at diagnosis, bone marrow involvement, and lymphoma cancer cells in the ... Many chemotherapy agents, and specifically Rituxan® (rituximab), have shown activity ... Cancer Consultants (press release),

Arthritis Blog Archives -- Mar 2, 2006
Rituxan, the world's best-selling cancer drug has been FDA-approved to treat rheumatoid arthritis patients. Rituxan is to be used ... About - News & Issues,

Biotec Pharmacon Announces Good Progress in ongoing Clinical ... -- Feb 28, 2006
...in Oslo, where SBG will be tested in combination with cancer antibodies against breast cancer (Herceptin) and non-Hodgkin’s lymphoma (Rituxan). ... PharmaLive.com (press release),

TECH TICKER -- Mar 1, 2006
Genentech said Tuesday that it has won federal approval to use its cancer drug, Rituxan, as a treatment for some patients with arthritis. ... San Jose Mercury News,

Xencor Data Published in PNAS Show Engineering the ''Fc'' Region ... -- Mar 7, 2006
..."While antibodies such as Genentech's Rituxan are well known for their role in the treatment of cancer, many other promising antibodies are sub-optimal for use ... Genetic Engineering News,

DAILY DIGEST -- Mar 1, 2006
Genentech and Biogen Idec won federal approval on Tuesday to sell their cancer drug Rituxan as a treatment for rheumatoid arthritis. ... San Francisco Chronicle,

Genentech Still 'Best Overall Story' In Biotech -- Mar 2, 2006
This is the first non-oncology indication for Rituxan, best known as a cancer drug with $1.8 billion in 2005 sales. Genentech (nyse ... Forbes

Drug Stocks Tempered By Lofty Expectations -- Mar 4, 2006
The approval marked the first noncancer indication for Rituxan, which logged sales ... received priority review status for a new indication for cancer drug Revlimid ... Forbes

Biovest International Submits Amendment Request To FDA For Use Of ... -- Feb 26, 2006
...basis of BiovaxID and its implications for this otherwise fatal cancer. ... By contrast, Rituxan® (rituximab) a passive immunotherapeutic consisting of a ... Medical News Today (press release),

Biogen Idec says it's rebounding strongly -- Mar 13, 2006
...successes. Earlier this month, the FDA approved the company's Rituxan, a cancer drug, as a treatment for rheumatoid arthritis. A ... Boston Globe,

PRESS DIGEST - Washington Post Business - March 1 -- Feb 28, 2006
The cancer drug Rituxan won federal approval to treat an entirely different disease, rheumatoid arthritis, in a development that doctors called a symbol of ... Reuters

London drug trial volunteers in critical condition -- Mar 14, 2006
More than 15 have reached the market, including Herceptin, Rituxan and Avastin for cancer and Humira and Remicade for arthritis. ... MSNBC

Genentech opens Louisville facility ahead of schedule -- Mar 6, 2006
...develops, manufactures and commercializes biotherapeutics for the treatment of cancer and other medical needs. It makes the drugs Rituxan, Herceptin, Avastin ... Louisville Business First,

Genentech stock jumps on earnings projection -- Mar 17, 2006
The company's top-selling drug, Rituxan, a treatment for rheumatoid arthritis and ... Avastin, the company's treatment for colorectal cancer that is combined with ... CNNMoney.com

TeGenero Mab causes shock side-effects in UK trial -- Mar 17, 2006
...and Roche, Genentech and Biogen Idec's leukemia treatment Rituxan/MabThara (rituximab ... medicines, particularly in chronic disorders such as cancer and multiple ... Pharmaceutical Business Review

Midday Business Report: O’Reilly jumps on earnings report -- Mar 1, 2006
The nation’s best-selling cancer drug has won federal approval as a ... action comes more than eight years after the agency initially approved Rituxan to treat ... Kansas City Star,

Carol G. Gallagher, Pharm. D., to Join Anadys Pharmaceuticals as ... -- Mar 22, 2006
During that time, her role included leadership of the Rituxan(R) collaboration ... medicines for the treatment of hepatitis, other serious infections, and cancer. ... PR Newswire (press release),

WeissComm Partners Adds New Clients and Expands Staff to Meet ... -- Mar 14, 2006
...therapeutics for benign prostatic hyperplasia and cancer; -- Cardica, which ... Relations, she supported Genentech's oncology products Rituxan, Herceptin and ... PR Newswire (press release),

Louisville has high hopes for Genentech -- Mar 7, 2006
It has built its recent success on blockbuster cancer drugs, including Rituxan for non-Hodgkin's lymphoma and Avastin for colon cancer. ... Louisville Courier-Journal,

Favrille Announces $45 Million Financing to Support Clinical ... -- Mar 7, 2006
...company developing patient-specific immunotherapies for the treatment of cancer, announced today ... trial is designed to evaluate FavId following Rituxan(R), the ... PR Newswire (press release),

US Stock-Index Futures Advance; GM Rises, Google Rebounds -- Mar 1, 2006
Biogen and Genentech Inc.'s cancer medicine Rituxan won US approval for use in treating rheumatoid arthritis, a global market exceeding $5 billion. ... Bloomberg

Health briefs -- Mar 5, 2006
The FDA has approved the blockbuster drug Rituxan as a treatment for rheumatoid arthritis -- expanding its approved uses beyond cancer treatment. ... Chicago Sun-Times,

The Best-Selling Drugs In America -- Feb 27, 2006
...and Genentech's Rituxan grew 17% to $33 billion. These are often very expensive, injectable medicines used for hard-to-treat diseases like cancer, severe ... Forbes

Genentech buys Lonza’s GS Gene Expression System -- Feb 27, 2006
Lonza already has a commercial relationship with Genentech, producing around 50 per cent of the biotech's requirements for its cancer drug Rituxan over the ... In-PharmaTechnologist.com,

New treatments show promise for some diabetics -- Mar 7, 2006
The other antibody, anti-CD20, is also known as Rituxan, a drug co-marketed by Genentech Inc. and Biogen Idec Inc. for rheumatoid arthritis, cancer and other ... Pittsburgh Post Gazette,

Doctors wary of Biogen MS drug, survey says -- Mar 1, 2006
Separately yesterday, Biogen Idec said the FDA approved its cancer drug Rituxan for use in treating patients with rheumatoid arthritis. ... Boston Globe,

Treanda™ Has Significant Activity in Treatment of Recurrent NHL -- 25 Jan 2006
...of patients achieved an anticancer response with Treanda plus Rituxan. 33% of patients achieved a complete disappearance of detectable cancer (complete response ... Cancer Consultants (press release),

Genentech Share Price Currently A 'Good Entry Point' -- 25 Jan 2006
...per-share growth as well as “a number of potential new indications�? for Genentech’s colorectal cancer drug, Avastin, as well as for Rituxan, a treatment ... Forbes

GlycoFi announces the first production of antibodies with human ... -- Jan 22, 2006
...cell killing compared to Rituxan®. "By controlling the sugar structures on antibodies we have shown that the antibodies ability to kill cancer cells can be ... Biology News Net (press release),

Yeast Helps Drugs Work Better -- Jan 23, 2006
With this new method, the scientists were able to demonstrate an improved function of Genentech’s Rituxan, the best-selling cancer drug in the United States ... Red Herring,

Genetic Features Predict Response of Chronic Lymphocytic Leukemia ... -- Jan 20, 2006
...and the University of Chicago recently evaluated data from the Cancer and Leukemia ... study included 88 patients with CLL who were treated with Rituxan and Fludara ... Cancer Consultants (press release),

Off-Label Use of Blood Clotting Drug, NovoSeven, Linked to Deaths ... -- Jan 19, 2006
Biogen Idec Inc. of illegally promoting cancer drug Rituxan as a treatment for arthritis, a use not yet approved by regulators. ... Newsinferno.com,

BiovaxID, Personalized Anti-Cancer Vaccine from Biovest ... -- Jan 10, 2006
...tumor recurrence, which is the gold standard for cancer therapeutics.". ... Rituxan is a passive immunotherapeutic consisting of a monoclonal antibody administered ... PharmaLive.com (press release),

Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... -- Jan 13, 2006
Researchers from the MD Anderson Cancer Center have reported that the combination of Rituxan® (rituximab) and granulocyte macrophage-colony stimulating factor ... Cancer Consultants (press release),

Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... -- Jan 12, 2006
Researchers from MD Anderson Cancer Center have reported that the combination of Rituxan (rituximab) and granulocyte macrophage-colony stimulating factor ... Cancer Consultants (press release),

Favrille cancer product receives fast track status -- Jan 13, 2006
The drug is currently in a pivotal phase III clinical trial following Rituxan therapy (produced by Genentech) in patients with follicular B-cell NHL. ... Pharmaceutical Business Review

HuMax®-CD20 Safe and Effective Treatment for Relapsed/Refractory ... -- Jan 10, 2006
However, HuMax-CD20 uses different mechanisms to kill cancer than Rituxan; direct killing of the cells does not appear to occur with HuMax-CD20. ... Cancer Consultants (press release),

Genentech's 4th-Qtr Profit Climbs 64% on Cancer Drugs (Update2) -- Jan 10, 2006
Sales of Avastin have surpassed all of Genentech's other treatments except Rituxan, which is used against the blood cancer non-Hodgkin's lymphoma. ... Bloomberg

Genentech, Biogen Idec sued over Rituxan marketing -- Jan 12, 2006
...employee has sued the biotechnology company and marketing partner Biogen Idec Inc., accusing them of illegally promoting the cancer drug Rituxan as a treatment ... North County Times,

Genentech income rises 64% in quarter -- Jan 11, 2006
...with the successful launch of Avastin and its future potential.'' Avastin is one of Genentech's three main anti-cancer drugs, along with Herceptin and Rituxan. ... San Jose Mercury News,

UPDATE 1-Cancer drug sales lift Genentech quarterly profit -- Jan 10, 2006
US sales of breast cancer treatment Herceptin jumped 98 percent to $250.1 million, while US sales of Rituxan for non-hodgkin's lymphoma rose 13 percent from a ... Reuters

Genentech up 64% in quarter after good year on many fronts -- Jan 10, 2006
For the full year, Genentech's revenue reached a record $6.6 billion, fed by the sustained growth of its mainstay cancer drugs Rituxan, Herceptin and Avastin. ... San Francisco Chronicle,

Cancer drug sales lift Genentech quarterly profit -- Jan 10, 2006
But US sales of Rituxan for non-Hodgkin's lymphoma also disappointed Wall ... Genentech's new lung cancer treatment Tarceva recorded sales of $83.9 million, a 15 ... Reuters

Genentech Announces Full Year and Fourth Quarter 2005 Results -- Jan 10, 2006
...study of Rituxan in primary progressive multiple sclerosis, as well as in the Phase II combination study of Avastin and Tarceva in non-small cell lung cancer. ... MSN Money

GX15-070 Active in Refractory CLL -- Jan 10, 2006
...low-grade cancer. Standard treatment for CLL may include no treatment until disease progression, or treatment with chemotherapy, the targeted agent Rituxan, or ... Cancer Consultants (press release),

Hopes dashed for peanut allergy drug Xolair -- Jan 18, 2006
Genentech's top-selling products are Rituxan, a treatment for non-Hodgkin's lymphoma and Avastin, a treatment for colorectal cancer. News-Medical.net,

Genentech's Product Mix Could Boost Margins In 2006 -- Jan 11, 2006
...reported better-than-expected sales results for Avastin, its colorectal cancer treatment, as well as for Herceptin for breast cancer, and Rituxan for Non ... Forbes

Earnings Preview: Genentech -- Jan 9, 2006
Food and Drug Administration granted a priority review to Rituxan, which Genentech ... of Genentech's Tarceva drug to include its use against pancreatic cancer. ... BusinessWeek

Favrille gets FDA FavId fast track -- Jan 12, 2006
Favrille is testing the treatment following Rituxan for patients with follicular B-cell non-Hodgkin's lymphoma, a cancer of the immune system. ... BusinessWeek

Genentech/Biogen Idec: wearing the drug marketing suit well? -- Jan 12, 2006
17:03 GMT - An ex-Genentech employee has reportedly accused the company, and its marketing partner Biogen Idec, of illegally promoting cancer drug Rituxan as a ... Pharmaceutical Business Review

Accentia Stock Rises on Study Results -- Jan 10, 2006
...the patient's own cancer cells that aims to help the body recognize and attack cancer. ... and those who take drugs such as Genentech Inc.'s Rituxan to prevent ... MSN Money

Genentech's Shares Fall On Disappointing Avastin Sales -- Jan 11, 2006
An anti-CD20 antibody, Rituxan is partnered with Basel, Switzerland-based F ... Genentech's breast cancer drug, Herceptin (trastuzumab) posted fourth-quarter sales ... BioWorld Online (subscription),

More Upside Expected From Genentech -- Jan 10, 2006
Rituxan is expected to gain two new indications in first line non ... Similarly, Tarceva's recent approval in a pancreatic cancer indication should revive quarterly ... TheStreet.com

Favrille Receives FDA Fast Track Designation for FavId, Lead ... -- Jan 12, 2006
...developing patient-specific immunotherapies for the treatment of cancer, announced today ... in a pivotal Phase 3 clinical trial following Rituxan® therapy in ... Yahoo! News (press release)

Genentech sued by former worker -- Jan 12, 2006
...partner Biogen Idec Inc. of illegally promoting cancer drug Rituxan as a treatment for arthritis, a use not approved by regulators. ... Monterey County Herald,

Genentech's 4Q earnings meet expectations -- Jan 10, 2006
...product, the non-Hodgkin's lymphoma drug Rituxan, and a relative newcomer called Avastin that has been approved to treat the sickest colon cancer patients. ... Seattle Post Intelligencer

A real surprise -- Jan 11, 2006
...full-year 2005. The top-selling drug, Rituxan for cancer, climbed 16%. Other products experienced faster growth. Sales of cancer ... Reuters

Rituxan® Improves Survival in Patients with Follicular Lymphoma -- Dec 30, 2005
E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B have reported that the addition Rituxan (rituximab) to ... Cancer Consultants (press release),

Rituxan® Improves Survival in Patients with Follicular Lymphoma -- Dec 29, 2005
...of lymphocyte it involves and by the rate at which the cancer grows—both ... Rituxan is a monoclonal antibody that has been designed to recognize and bind to B ... Cancer Consultants (press release),

Genentech's Q4 profit jumps 64%, but shares slip -- Jan 11, 2006
The company's flagship drug, Rituxan (rituximab), which is used to treat non ... new kid on the block, Avastin (bevacizumab), cleared to treat colon cancer by the ... Pharma Times (subscription),

Former worker sues Genentech over drug marketing -- Jan 12, 2006
PHILADELPHIA (Dow Jones/AP) - Genentech is facing more questions over the marketing of its cancer drug Rituxan. A former employee ... KGET 17,

Former worker sues Genentech over drug marketing -- Jan 11, 2006
...its marketing partner Biogen Idec of illegally promoting a cancer drug as a ... lawsuit last year alleging the companies' marketing of Rituxan defrauded government ... Eyewitness News,

BUSINESS DIGEST -- Jan 12, 2006
...former Genentech employee has accused the South San Francisco biotech company and marketing partner Biogen Idec of illegally promoting cancer drug Rituxan as a ... San Jose Mercury News,

HuMax®-CD20 Safe and Effective Treatment for Relapsed/Refractory ... -- Jan 11, 2006
The mechanism of action of HuMax-CD20 is different than for Rituxan® as apoptosis is not involved and resistant cells are apparently killed. ... Cancer Consultants (press release),

Breakthrough for MS -- Jan 17, 2006
Neurologist Olaf Stuve, MD, Ph.D., says the cancer drug rituximab (Rituxan) is the first treatment to target the B cells in patients with MS, and it could be ... News 14 Carolina,

Lonza pays 120 mln euros for UCB's bioproducts unit -- Jan 17, 2006
...won contracts to make substances used in fast-selling cancer treatments such as US firm Genentech's (DNA.N: Quote, Profile, Research) lymphoma drug Rituxan. ... Reuters

CVP Plus Rituxan® Provides Long-Term Benefits in Patients with ... -- Dec 29, 2005
A multi-center randomized international trial determined that the addition of Rituxan® (rituximab) to CVP (cyclophosphamide, vincristine, and prednisone ... Cancer Consultants (press release),

Genentech: An expensive darling -- Jan 9, 2006
...top products are: Herceptin, a breast cancer treatment for patients with a specific gene; Avastin, a treatment for colorectal cancer; and Rituxan, a treatment ... CNN/Money

ZEVALIN® Radioimmunotherapy May Play Greater Role In Combination ... -- Dec 27, 2005
...who have failed to adequately respond to other cancer therapies ... B cell non Hodgkin's lymphoma, including patients with rituximab (RITUXAN) refractory follicular ... Medical News Today (press release),

News in Brief -- Jan 12, 2006
...(BIIB), Cambridge, Mass., of illegally promoting cancer drug Rituxan as a treatment for arthritis, a use not yet approved by regulators. ... San Francisco Examiner,

Targeted cancer therapies: Another step forward -- Dec 22, 2005
Rituxan will enjoy label expansion and increased market penetration, with forecast ... move into the adjuvant treatment setting for breast cancer, with forecast ... News-Medical.net,

Targeted cancer therapies: another step forward -- Dec 23, 2005
...targeted therapies have brought progress in the treatment of cancer, it would ... mainly by five key products: Genentech/Roche’s Rituxan (rituximab), Herceptin ... Pharmaceutical Business Review

Small Molecule Bcl-2 Protein Inhibitor, GX15-070, Active for ... -- Jan 12, 2006
Researchers from MD Anderson Cancer Center, the University of California at San ... patients with CLL refractory to fludarabine, alkylators and to Rituxan® and 40 ... Cancer Consultants (press release),

Genentech Asks OK for Eye Drug -- Dec 30, 2005
...drug Tarceva on November 2 for use against pancreatic cancer in combination with chemotherapy, and is reviewing its non-Hodgkin’s lymphoma drug Rituxan as a ... Red Herring,

Biotech Racks Up Another Impressive Quarter to Close Year in ... -- Jan 3, 2006
...protective chemotherapy agent used to treat late-stage breast cancer; Targretin, a ... Positive results of a Phase III clinical study of Rituxan (Rituximab) in ... PR Newswire (press release),

Drugs from Chimeric Chickens -- Jan 16, 2006
...assays, a feat that could augur well for Genentech’s Rituxan and Herceptin ... Cancer patients are still many regulatory trials away off from being treated with ... Red Herring,

Genelabs suffers setback on lupus drug -- Jan 16, 2006
One hope for sufferers of the disorder lies with Genetech/Biogen Idec's cancer drug Rituxan (rituximab), which is already on the market for non-Hodgkin's ... Pharma Times (subscription),

Genentech said to halt allergy tests -- Jan 16, 2006
...products are Rituxan, a treatment for non-Hodgkin's lymphoma that totaled $1.8 billion in US sales in 2005, and Avastin, a treatment for colorectal cancer with ... CNN/Money

Genentech Puts Science Over Commercial -- Dec 29, 2005
It has developed three of the most important targeted cancer drugs to date, eg, Herceptin for breast cancer, Rituxan for lymphoma and Avastin for numerous ... Patent Baristas,

Wyeth's Biotech Bet -- Jan 4, 2006
...develop, and commercialize medicines for inflammatory disease and cancer based on the ... Rituxan, a drug approved to treat non-Hodgkins lymphoma and marketed by ... Motley Fool

Targeted cancer therapies: another step forward -- 23 Dec 2005
...targeted therapies have brought progress in the treatment of cancer, it would ... mainly by five key products: Genentech/Roche’s Rituxan (rituximab), Herceptin ... Pharmaceutical Business Review

Targeted cancer therapies: Another step forward -- Dec 22, 2005
Rituxan will enjoy label expansion and increased market penetration, with forecast ... move into the adjuvant treatment setting for breast cancer, with forecast ... News-Medical.net,

Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin -- Dec 19, 2005
About two-thirds of those patients have lung cancer. ... tiuxetan), was well tolerated and had synergistic activity in patients with Rituxan (rituximab)-refractory ... BioWorld Online (subscription),

Rituxan® and CHOP for Elderly Patients with Diffuse Large B-Cell ... -- Dec 19, 2005
...of lymphocyte it involves and by the rate at which the cancer grows—both ... Rituxan is a monoclonal antibody that has been designed to recognize and bind to B ... Cancer Consultants (press release),

Genentech Submits Supplemental Biologics License Application for ... -- Dec 19, 2005
Genentech is committed to changing the way cancer is treated by ... Genentech is leading clinical development programs for Rituxan® (Rituximab), Herceptin ... Yahoo! News (press release)

Biotechs may be a good bet for 2006 -- Dec 21, 2005
It has three top products: Rituxan and Herceptin, both breast cancer treatments for specific genes; and Avastin, a treatment for colorectal cancer. ... CNN

Reasonable premium -- Dec 20, 2005
Although the growth rate for sales of cancer product Rituxan was lower than for some of DNA's other products (up 16%), it is important to keep in mind that ... Reuters

Genentech Submits Supplemental Biologics License Application for ... -- Dec 19, 2005
Genentech BioOncology Genentech is committed to changing the way cancer is treated ... Genentech is leading clinical development programs for Rituxan(R) (Rituximab ... PR Newswire (press release),

Maintenance therapy with RITUXAN(R) dramatically improves survival -- Dec 12, 2005
...a standard chemotherapy regimen or Rituxan plus CHOP as induction therapy (a treatment designed as a first step toward reducing the number of cancer cells). ... CNW Telbec (Communiqués de presse),

Adding Radioimmunotherapy To Chemotherapy Reduces Relapse Risk In ... -- Dec 17, 2005
...of chemotherapeutic drugs plus a monoclonal antibody (CHOP and Rituxan®), but the ... tiuexetan) is a monoclonal antibody bound with a cancer-killing radioisotope ... Medical News Today (press release),

Favrille: FavId Improves Cancer Drugs -- Dec 13, 2005
Mid-stage clinical trial data showed the company's FavId treatment increased the clinical response rate to the cancer therapy Rituxan to 65 percent from 49 ... MSN Money

Euroshares outlook - slightly higher ahead of FOMC meeting -- Dec 12, 2005
Swiss peer Roche will ask European regulators to extend the label for its top-selling Rituxan cancer medicine after a study showed that the treatment halves ... Forbes

European Stocks Such as BP, Pernod May Advance; BASF May Drop -- Dec 12, 2005
The company said after markets closed yesterday that it will ask European regulators to extend the label for its top-selling Rituxan cancer medicine, after a ... Bloomberg

Pilot Clinical Study of Genasense(R) Plus Rituxan(R) and ... -- Dec 12, 2005
...sodium) Injection, in combination with fludarabine plus rituximab (Rituxan®; Genentech/IDEC ... the biochemical pathway known as apoptosis whereby cancer cells are ... Yahoo! News (press release)

Rituxan® is an Effective for “Purging�? of Stem Cell Grafts ... -- Dec 15, 2005
Researchers from Case Western Reserve and Cancer Center have reported that in-vivo purging with Rituxan® (rituximab) is effective as or more effective than ex ... Cancer Consultants (press release),

Six Cycles of Bi-Weekly R-CHOP Standard for Elderly with Diffuse ... -- Dec 19, 2005
Researchers affiliated with the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) have reported that 6-cycles of Rituxan® (rituximab) and CHOP ... Cancer Consultants (press release),

Studies of Nipent(R) in Combination Cancer Therapies for Treatment ... -- Dec 9, 2005
...publication only in Blood 1. Abstract #4750 A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in ... PR Newswire (press release),

Roche seeks wider use of top cancer drug MabThera -- Dec 12, 2005
...selling drug MabThera in the treatment of non-Hodgkin's Lymphoma, a cancer of the ... in the United States, where the product is known as Rituxan, a spokeswoman ... Reuters

Favrille Reports Positive Data from Phase 2 Clinical Trial of ... -- Dec 13, 2005
...for the treatment of cancer, reported positive long-term follow-up data from its Phase 2 clinical trial of FavId(R) following Rituxan(R) treatment in patients ... PR Newswire (press release),

Pharmacyclics Announces Presentation and Publication of ... -- Dec 12, 2005
...selectively target and disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic ... Rituxan® is a registered trademark of Genentech ... Yahoo! News (press release)

Hana Biosciences Announces Changes to Strengthen Management Team -- Dec 16, 2005
Before joining Hana, Vitale led the Rituxan(R) (rituximab) commercial team and ... development, licensing and life cycle management for cancer products including ... Business Wire (press release),

New Data Demonstrate ZEVALIN(R) Radioimmunotherapy May Play ... -- Dec 13, 2005
...who have failed to adequately respond to other cancer therapies ... B cell non Hodgkin's lymphoma, including patients with rituximab (RITUXAN) refractory follicular ... Genetic Engineering News,

New Data Demonstrate ZEVALIN(R) Radioimmunotherapy May Play ... -- Dec 13, 2005
...who have failed to adequately respondto other cancer therapies. ... B cell non Hodgkin's lymphoma, including patients withrituximab (RITUXAN) refractory follicular ... Finanzen.net,

Cephalon Oncology Reports High Response Rates to Single Agent ... -- Dec 12, 2005
...and marketing of innovative products to treat sleep and neurological disorders, cancer and pain. ... Rituxan(R) is a registered trademark of Genentech, Inc. ... PR Newswire (press release),

ZymoGenetics Highlights Development Programs at Analyst & Investor ... -- Dec 8, 2005
...trials, largely because IL-21 has been shown in preclinical studies to activate several cell types involved in the anti-cancer mechanism of Rituxan(R). A ... PR Newswire (press release),

Blockbuster Drugs Rituxan, Avastin, and Erbitux Changes the Way ... -- Dec 5, 2005
The blockbuster drugs Rituxan, Avastin, and Erbitux have changed the way the industry looks upon antibody treatment of cancer in the same way that Taxol ... Genetic Engineering News,

ASH: Experimental Chemotherapy Drug Effective Against Resistant ... -- Dec 14, 2005
...refractory NHL, chronic lymphocytic leukemia, multiple myeloma, and breast cancer. ... regimens containing alkylating agents, or following treatment with Rituxan. ... MedPage Today,

Viragen Holds Annual Stockholder Meeting: CEO Issues Progress ... -- Dec 15, 2005
...this year, we reported that VG102 was found to significantly enhance the activity of rituximab (Rituxan(R); Genentech/IDEC), a leading cancer medication, when ... PR Newswire (press release),

Scientific Advances on Three Lead Cephalon Oncology Compounds to ... -- Dec 8, 2005
...arsenic trioxide) injection, the company's marketed anti-cancer therapeutic ... traditional alkylators and the monoclonal antibody rituximab (Rituxan(R)). Cephalon ... PR Newswire (press release),

MABTHERA MAINTENANCE THERAPY DRAMATICALLY IMPROVES SURVIVAL FOR ... -- Dec 12, 2005
NHL, representing about 45% of NHL patients, is a slow developing but serious cancer of the ... MabThera is known as Rituxan in the United States, Japan and Canada ... ITNews,

Cephalon Oncology Reports High Response Rates to Single Agent ... -- Dec 12, 2005
...disease after prior treatment with the antibody therapy rituximab (Rituxan(R)); a ... Clinical Research at the University of Rochester Wilmot Cancer Center in ... PharmaLive.com (press release),

Cephalon Oncology Reports High Response Rates to Single Agent ... -- Dec 12, 2005
...after prior treatment with the antibody therapy rituximab (Rituxan®); a subgroup also ... Clinical Research at the University of Rochester Wilmot Cancer Center in ... Yahoo! News (press release)

R-CHOP Improves Outcomes as Initial Therapy in Follicular Lymphoma -- Nov 28, 2005
No conclusion has been made about whether using Rituxan as part of initial therapy is more beneficial than using it once cancer has progressed. ... Cancer Consultants (press release),

Cancer Group Lists Top Treatment Advances for 2005 -- Dec 2, 2005
Other notable advances included the success of the drug oxaliplatin in fighting colon cancer recurrence; the use of Rituxan and Bexxar combination therapy ... Forbes

Scientific Advances on Three Lead Cephalon Oncology Compounds to ... -- Dec 8, 2005
...arsenic trioxide) injection, the company's marketed anti-cancer therapeutic ... from both traditional alkylators and the monoclonal antibody rituximab (Rituxan®). ... Yahoo! News (press release)

Nipent®/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... -- Nov 23, 2005
Mayo Clinical have reported that the treatment combination consisting of Nipent (pentostatin), Cytoxan (cyclophosphamide) and Rituxan (rituximab) demonstrates ... Cancer Consultants (press release),

Pharma Reformulates -- Dec 5, 2005
...angiotensin antagonists (heart failure), and aromatase inhibitors (the adjuvant treatment of early breast cancer in postmenopausal women). Rituxan, already a ... Chemical & Engineering News

ZymoGenetics Announces Presentation of TACI-Ig Phase 1 Preliminary ... -- Dec 12, 2005
...and one discussing preclinical use of Interleukin 21 (IL-21) with Rituxan(R) were ... ZymoGenetics is developing IL-21 for the treatment of cancer, initially in ... PR Newswire (press release),

Bristol-Myers' Orencia Has 'Bullish Prospects' -- Dec 13, 2005
Rituxan, a cancer drug marketed by Genentech (nyse: DNA - news - people ), also awaits approval for treatment of rheumatoid arthritis. ... Forbes

Biogen Idec's executive chairman to retire this month -- Dec 8, 2005
At Idec, Rastetter championed the monoclonal antibody that became Rituxan, one of the most successful cancer drugs ever. He also ... Boston Globe,

Favrille Announces Appointment of David Guy as Chief Commercial ... -- Dec 5, 2005
...developing patient-specific immunotherapies for the treatment of cancer, announced today the ... in a pivotal Phase 3 clinical trial following Rituxan(R) treatment ... PharmaLive.com (press release),

Peptech announces Domantis continues development momentum -- Dec 7, 2005
Even blockbuster antibody therapeutics such as Rituxan are aimed at killing all B ... cells Domantis hopes to develop the next generation of cancer drugs, based on ... Biotech Intelligence (press release),

Biogen Idec kondigt aftreden aan van William H. Rastetter als ... -- Dec 7, 2005
Bill Rastetter's drive and unyielding commitment to those we serve that resulted in bringing RITUXAN(R) (rituximab), the world's leading cancer therapeutic, to ... Netherlands Corporate News,

Roche's MabThera dramatically improves survival for lymphoma ... -- Dec 12, 2005
...chances of survival for patients suffering from indolent non-Hodgkin's Lymphoma (NHL), a cancer of the ... The drug is known as Rituxan in the US, Japan and Canada ... Forbes

Montgomery & Co., LLC Initiates Coverage on Genentech Inc. (DNA) -- Nov 27, 2005
Genentech is a biotech company focused on cancer therapies. Product sales in 2004 were driven primarily by Avastin, Rituxan and Herceptin, all of which are ... dBusinessNews San Francisco (press release),

Genentech: Good Company, Bad Investment -- Dec 12, 2005
The company is responsible for such widely prescribed cancer-fighters as Rituxan and Herceptin, as well as Avastin, a recent "blockbuster" drug that chokes off ... Motley Fool

Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical ... -- Dec 7, 2005
...for the treatment of cancer, announced today that long-term follow-up data from its Phase 2 clinical trial of FavId(R) following Rituxan(R) treatment in ... PharmaLive.com (press release),

Around the world with10 foreign stocks -- Dec 4, 2005
...dominance of the oncology field, supplying widely used medicines such as breast-cancer drug Herceptin, colorectal treatment Avastin, and Rituxan, which treats ... Investor's Business Daily (subscription)

BioCryst Out-Licenses BCX-4208 To Roche In Potential $560M Deal -- Nov 30, 2005
...area, as well as a recent study that showed that Rituxan (rituximab) is ... Beyond cancer, the company's portfolio has gained recent attention for its antiviral ... BioWorld Online (subscription),

Biotech Earnings Jump In Quarter -- 21 Nov 2005
...million was aided by unapproved use as an adjuvant in breast cancer therapy ... Also important was the non-Hodgkin’s lymphoma treatment Rituxan, which the company ... Chemical & Engineering News

Rituxan's use spreads to arthritis -- Nov 17, 2005
Genentech Inc. and Biogen Idec Inc.'s Rituxan cancer medicine soon may be sold to treat rheumatoid arthritis, a global market exceeding $5 billion. ... Inside Bay Area,

Pentostatin/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... -- Nov 17, 2005
...and Cytoxan® (cyclophosphamide) and the monoclonal antibody Rituxan® (rituximab) produces ... CLL is a cancer involving the lymph (immune) system, which includes ... Cancer Consultants (press release),

Cancer drug helps arthritis -- study -- Nov 14, 2005
...and Biogen Idec Inc.'s cancer drug Rituxan improved symptoms of rheumatoid arthritis in patients not helped by drugs designed to block an inflammation-causing ... ABC News

Positieve resultaten van Phase III onderzoek Rituxan bij ... -- Nov 15, 2005
...in diagnostics, the leading supplier of medicines for cancer and transplantation ... This press release contains forward-looking statements regarding RITUXAN as a ... Netherlands Corporate News,

Favrille Announces New Data From Phase 2 Clinical Trial of FavId ... -- Nov 15, 2005
...developing patient-specific immunotherapies for the treatment of cancer, announced today the ... Phase 2 clinical trial of FavId(R) following Rituxan(R) therapy in ... PR Newswire (press release),

Cancer drug trial results touted -- Nov 10, 2005
...trial involving 38 people and pixantrone, the company said the median time for patients who received the experimental treatment and Rituxan, a cancer drug on ... Seattle Post Intelligencer

Talbots reports 3.1% drop in 3d-quarter net income -- Nov 16, 2005
...(Bloomberg). Biogen Idec Inc., of Cambridge, said its cancer drug Rituxan showed positive results in treating patients with rheumatoid arthritis. ... Boston Globe,

Roche's MabThera helps arthritis patients -- Nov 15, 2005
...drug is already indicated as a treatment for non-Hodgkin's lymphoma, or lymph cancer. ... BIIB.O: Quote, Profile, Research) and is marketed in the US as Rituxan. Reuters

Addition of Pixantrone to Rituxan Therapy Significantly Prolongs ... -- Nov 9, 2005
...to moderate and consistent with the known safety profile for Rituxan monotherapy, except ... activity and safety of the anthracycline family of anti-cancer agents. ... PharmaLive.com (press release),

After 34 Years, Goals Change In Medicine's 'War On Cancer' -- Nov 11, 2005
Genentech, (DNA) with such drugs as Herceptin, Rituxan and Avastin, is one ... Cancer fighters hope that these therapies can advance enough to replace chemotherapy ... Investor's Business Daily (subscription)

INEX to Spin Off Targeted Immunotherapy Assets -- Nov 17, 2005
...and breast cancer models. Data presented in a preclinical model of lymphoma demonstrated that treatment with the monoclonal antibody rituximab (Rituxan(R ... PR Newswire (press release),

Patients, Industry and Lawmakers Seek to End SBA Bureaucratic ... -- Nov 9, 2005
Katy Anderson, a Chevy Chase, Md. mother of three who survived cancer due to Rituxan therapy, shared her story at BIO's press conference. ... PR Newswire (press release),

FDA to speed ruling on uses of Biogen cancer drug -- Oct 26, 2005
States in 1997 and is the core of Biogen Idec's cancer-drug franchise, which the company is hoping to grow. It is also conducting trials to show Rituxan is an ... Boston Globe,

Genentech/Biogen cancer drug granted priority review by FDA -- Oct 27, 2005
Rituxan is already sold as a treatment for less severe forms non-Hodgkins lymphoma in relapsed or refractory patients. Non-Hodgkins lymphoma a cancer of the ... Pharmaceutical Business Review

Cell hits treatment goals, but stock is sold -- Nov 11, 2005
...clinical trial compared pixantrone in combination with Rituxan — the first monoclonal antibody approved in the US for treating cancer — to Rituxan alone. ... Seattle Times,

Biogen revises warning label for cancer drug -- Oct 29, 2005
...of Cambridge has revised the warning label for its cancer treatment Zevalin ... Zevalin is administered in conjunction with Biogen Idec's Rituxan for non-Hodgkin's ... Boston Globe,

Rituxan® as Maintenance Therapy Reduces Relapses in Non-Hodgkin ... -- Oct 28, 2005
Results from previous trials have indicated that Rituxan in addition to chemotherapy may improve anticancer response rates delay cancer progression; however ... Cancer Consultants (press release),

Cancer-fighting drug warning level raised -- Oct 31, 2005
Zevalin is used with the cancer drug Rituxan when no other treatments of non-Hodgkin's lymphoma work. Drug maker Biogen Idec Inc. ... United Press International

Perceptions of My Life: A Cancer Journal -- Oct 23, 2005
...this journal for anyone who has just been diagnosed with cancer for the ... lymph node growth, then received treatment with a new medication, Rituxan, and finally ... News Record,

Genentech says FDA gives Rituxan priority review -- Oct 25, 2005
...(DNA.N: Quote, Profile, Research) and Biogen Idec Inc.(BIIB.O: Quote, Profile, Research) said on Tuesday said their cancer drug Rituxan will get a speedy ... Reuters

FDA Approves Tarceva in Combination with Gemcitabine Chemotherapy ... -- Nov 2, 2005
Genentech is committed to changing the way cancer is treated by ... Genentech is leading clinical development programs for Rituxan(R) (Rituximab), Herceptin(R ... PharmaLive.com (press release),

Multimedia News Release -- FDA Approves Tarceva(R) in Combination ... -- Nov 3, 2005
Genentech BioOncology Genentech is committed to changing the way cancer is treated ... Genentech is leading clinical development programs for Rituxan(R) (Rituximab ... PR Newswire (press release),

UPDATE 1-J&J, Schering-Plough RA drug shows promise in trial -- Nov 16, 2005
...(BIIB.O: Quote, Profile, Research) recently filed for marketing approval to sell their cancer drug Rituxan as a treatment for rheumatoid arthritis in patients ... Reuters

FDA Grants Priority Review for Rituxan(R) Supplemental Biologics ... -- Oct 25, 2005
According to the American Cancer Society, more than 56,000 men and women in the United States are diagnosed with NHL each year. Rituxan Safety Profile In NHL ... PR Newswire (press release),

FDA Grants Priority Review for Rituxan(R) Supplemental Biologics ... -- Oct 25, 2005
According to the American Cancer Society, more than 56,000 men and women in ... of patients experience infusion-related symptoms with their first Rituxan infusion. ... PR Newswire (press release),

Versatile Rituxan gets arthritis review -- Nov 1, 2005
...and Biogen Idec Inc.'s Rituxan, a cancer drug being considered for wider use against non-Hodgkin's lymphoma, has also won priority review as a treatment for ... Inside Bay Area,

FDA eyes wider use of Rituxan -- Oct 26, 2005
Genentech Inc. and Biogen Idec Inc. said they won a priority review from US regulators for wider use of the best-selling cancer drug Rituxan. ... Inside Bay Area,

Disease Modification in Rheumatoid Arthritis - Pipeline Uptake ... -- Nov 17, 2005
...between the next DMARDs to be launched, Rituxan/MabThera (rituximab) and Orencia (abatacept). Rituximabs promising dosing and use in cancer indications gives ... Business Wire (press release),

Favrille Reports Third Quarter 2005 Financial Results -- Nov 2, 2005
...suited for a slow growing cancer such as indolent B-cell NHL. We believe that the combination of passive and active immunotherapies -- Rituxan followed by ... PR Newswire (press release),

Innovative Drug Tarceva Now Available in Europe to Tackle Growing ... -- Oct 30, 2005
...and academia is what makes it possible for Roche to provide more effective cancer therapies. In the United States Herceptin, MabThera (Rituxan), Avastin and ... Antara,

利用鸡蛋生产抗癌�?�物 -- Oct 28, 2005
...that Viragen might be able to help Genentech, a California biotech, produce Herceptin, a gene-targeted treatment for breast cancer, and Rituxan, a treatment ... 中国生物技术信�?�网,

Biogen Says 3rd-Qtr Profit Fell on Increased Costs (Update1) -- Oct 26, 2005
...drug for MS rose 8 percent to $375 million. The company is depending on it and the eight-year-old cancer drug Rituxan for revenue. ... Bloomberg

A recent United States study has indicated that the drug Herceptin ... -- Oct 21, 2005
...a rare cancer that can recur after surgery. The catch is that 4 tablets must be taken daily for life which can cost up to $4,000 per month. Rituxan treats ... TODAYonline,

Tackling lymphoma -- Oct 29, 2005
..."There are some (new medicines on the market), like Rituxan, that specifically ... According to Hoge's Web site, NHL is the fifth most common cancer in the United ... Daily News Journal (subscription),

Reuters Summit-Roche says arthritis new business pillar -- Nov 9, 2005
...need that MRA and MabThera -- which is also known as Rituxan -- could address. ... its large pipeline of promising new medicines, particularly for cancer, where it ... Reuters

Spectrum Pharmaceuticals Reports Third Quarter 2005 Financial and ... -- Nov 4, 2005
...at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics to ... trial in refractory non-Hodgkin's lymphoma, especially in Rituxan(R) failures ... PR Newswire (press release),

Genentech, Biogen granted priority review by US FDA for sBLA to ... -- Oct 25, 2005
...have been granted priority review by the US FDA to the supplemental Biologics License Application (sBLA) submitted for their cancer drug Rituxan. ... Forbes

FDA and Biogen Idec Issue Drug Safety Alert Concerning Fatal ... -- Oct 30, 2005
REACTIONS sections of the Prescribing Information for the cancer drug Zevalin. ... Similar events have been associated with Rituxan (rituximab), a component of the ... Newsinferno.com,

The solution to costly drugs: Chickens -- Oct 26, 2005
...help Genentech (up $1.58 to $89.95, Research), a California biotech, produce Herceptin, a gene-targeted treatment for breast cancer, and Rituxan, a treatment ... CNN

Pharma, biotech, post mixed finances. -- Oct 31, 2005
Avastin revenue climbed 78 per cent to $325.2 million and Herceptin breast-cancer drug sales rose 70 per cent to $215.1 million. Sales of Rituxan for non ... in-PharmaTechnologist,

Biogen Says 3rd-Qtr Profit Fell on Increased Costs (Update2) -- Oct 26, 2005
At the same time, sales of Biogen's nine-year-old Avonex drug for MS rose 8 percent to $375 million, while its eight-year-old cancer drug Rituxan brought in ... Bloomberg

FDA grants speedy review to Biogen, Genentech drug -- Oct 31, 2005
...the FDA granted a similar speedy review to an application to expand Rituxan's use as a ... It has been used since 1997 to treat the cancer of the lymph system in ... Reuters

Genentech, Biogen push biotech stocks higher -- Oct 31, 2005
Biogen and Genentech said the FDA has accepted their application to have their cancer drug Rituxan approved also for the treatment of rheumatoid arthritis. ... Investor's Business Daily (subscription)

Genentech, Biogen get priority review -- Oct 25, 2005
...say the FDA has agreed to a priority review of their application to expand the use of Rituxan. The drug is being developed as a treatment for a cancer of the ... Providence Eyewitness News,

FDA decision boosts Biogen Idec -- Oct 31, 2005
Rituxan already is on the market for the treatment of certain types of cancer. Cambridge, Mass.-based Biogen Idec has 560 employees in Research Triangle Park. Raleigh Triangle Business Journal,

Update 1: Biogen Idec 3Q Profit Falls 27 Percent -- Oct 26, 2005
...a newer MS drug in February amid safety concerns, reported a 14 percent increase in revenue from Rituxan. Biogen Idec co-promotes the cancer drug with ... Forbes

Roche says arthritis new business pillar -- Nov 9, 2005
...on MRA and MabThera, which is already an established anti-cancer treatment, will ... need that MRA and MabThera -- which is also known as Rituxan -- could address. ... Reuters

(PRN) - Avista Advantage Acquisition of TelAssess Bolsters Product ... -- Nov 10, 2005
...(PRN) - The Pennsylvania Breast Cancer Coalition Thanks ... (PRN) - Biogen Idec and Genentech Announce November 16th Webcast Discussion of Rituxan Data Presented ... Bolsamania.com,

AnorMED reports fiscal 2006 second quarter results, and progress ... -- Nov 8, 2005
September, Phase II results, from a study involving 25 cancer patients undergoing ... with different therapies and patient populations, such as with Rituxan and in ... PR Newswire (press release),

Biotech Has October Blues -- Nov 1, 2005
Accentia's Biovaxid autologous cancer vaccine is in Phase III testing to ... Biologics License Application (sBLA) submitted by them for Rituxan (Rituximab) for ... PR Newswire (press release),

Biogen Idec third-quarter profit falls 26 pct -- Oct 26, 2005
...to safety concerns, also wrote off $25 million related to the cancer drug Zevalin ... Biogen also posted $182 million in co-promotion profit from Rituxan, the non ... Reuters

Phase III MabThera maintenance trial in lymphoma shows positive ... -- Oct 30, 2005
MabThera is known as Rituxan in the United States, Japan and Canada. ... leader in diagnostics, the leading supplier of medicines for cancer and transplantation ... Medical News Today (press release),

Roche continues to post strong growth through third quarter -- Oct 19, 2005
...cell lung cancer and in metastatic breast cancer. Regulatory filings for these new indications are planned for next year. Sales of MabThera/Rituxan, for non ... Biotech Intelligence (press release),

Genetic map indicates individualised drug therapies -- Oct 27, 2005
...data to look at conditions including diabetes, Alzheimer's disease, cancer, schizophrenia, asthma ... Roche's product MabThera/Rituxan, which has been used to treat ... Drug Researcher.com,

Many Questions for Biogen -- Oct 25, 2005
One revenue stream that Biogen investors can count on now is the cancer drug Rituxan, co-marketed with Genentech. When Genentech released earnings on Oct. ... Smartmoney.com

Tamiflu sales gives booster to Roche -- Oct 19, 2005
...cancer drug Avastin up 148pc to 1.1bn Swiss francs, NHL drug MabThera/Rituxan -- its top selling drug -- up 22pc to 3.0bn and breast cancer drug Herceptin up ... Business World,

Roche shares touch record amid panic buying of bird flu treatment -- Oct 19, 2005
Three of Roche's top 10 drugs are Genentech cancer treatments - including its highest selling drug, Rituxan, which is used to treat non-Hodgkin's lymphoma, a ... Guardian Unlimited,

Roche sales soar on demand for bird flu drug -- Oct 19, 2005
SFr1.1bn in the first nine months, while Herceptin, for breast cancer, climbed by 38 ... also pointed to important data coming on the use of Rituxan in rheumatoid ... MSNBC

Roche sees FY 2005 Tamiflu sales 1.1-1.2 bln sfr UPDATE -- Oct 19, 2005
The company added in a press conference here that the lymphoid cancer drug MabThera (Rituxan) is seen achieving sales above 4 bln eur in 2005. ... Forbes

Swiss shares close higher led by luxury goods stocks, banks, Roche ... -- Oct 25, 2005
Biogen Idec have been granted priority review by the US FDA to the supplemental Biologics Licence Application (sBLA) submitted for their cancer drug Rituxan. ... Forbes

Roche 9-mths sales up 17 pct, narrowly beats consensus UPDATE -- Oct 18, 2005
Oncology sales alone rose 37 pct, with sales of colorectal cancer drug Avastin up 148 pct to 1.1 bln sfr, NHL drug MabThera/Rituxan -- its top selling drug ... Forbes

Roche Has By Far Strongest Drug Business -- Oct 19, 2005
Sees significant upside from upcoming news flow on use of cancer drug Rituxan in rheumatoid arthritis, and from drug candidate MRA, which also treats ... New Ratings

Biogen Idec Q3 profits fall 26% -- Oct 27, 2005
Avonex. Biogen Idec witnessed 14% sales growth for its cancer drug, Rituxan, which is co-promoted by Genentech (DNA). Biogen Idec's ... New Ratings

(PRN) - Webcast Alert: Energias do Brasil Announces First 9M05 ... -- Oct 25, 2005
...[+]. (PRN) - Broad Range of SGI Solutions to Help National Cancer Institute Solve Demanding ... [+]. (PRN) - FDA Grants Priority Review for Rituxan(R) Supplemental ... Bolsamania.com,

Roche and Epitomics enter rabbit MAbs agreement -- Oct 19, 2005
...the discovery and development of monoclonal antibodies to treat cancer and other ... The market leaders include Roche/Genentech's Rituxan/MabThera (rituximab) and ... in-PharmaTechnologist,

More information on Rituxan from the National Cancer Institute

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:

Stop or slow the growth of cancer cells.
Make it easier for your immune system to destroy, or get rid of, cancer cells.
Keep cancer from spreading to other parts of your body.